David Grayzel photo
Investor profile

David Grayzel

Managing Director, Atlas Venture

About

David Grayzel is a physician-turned-venture capitalist at Atlas Venture who repeatedly co-founds and takes on CEO or chair roles at the biotech companies he backs, rather than staying purely on the investing side like most VCs. He specializes in immune system therapeutics and has co-founded multiple companies in areas like autoimmunity and oncology, including Surface Oncology, Q32 Bio, and Comanche Biopharma. David Grayzel is a physician-turned-venture capitalist at Atlas Venture who repeatedly co-founds and takes on CEO or chair roles at the biotech companies he backs, rather than staying purely on the investing side like most VCs. He specializes in immune system therapeutics and has co-founded multiple companies in areas like autoimmunity and oncology, including Surface Oncology, Q32 Bio, and Comanche Biopharma.

Works at

Investment focus

Stages
Seed
Series A
Sectors
BioTech
Health

Investment details

Avg check size$500K - $1M
Can lead rounds
No
Geographies
USA